On August 29, Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company’s total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. Non-IFRS loss narrowed by 31%, and gross margin excluding non-cash items was 76.4%. As of the end of June, the Company maintained a solid cash balance of RMB 1.6 billion. Additionally, with the successful completion of a share placement on August 1, which generated net proceeds of HK$1.553 billion, Everest’s total cash position increased further, providing a strong foundation for commercialization expansion and R&D investment. Supported by the excellent performance of its core products, Everest remains confident in achieving its full-year revenue guidance of RMB 1.6 to 1.8 billion and expects to turn operating cash flow positive in Q4.BOCOM International released its latest report today, noting that the strong sales performance of Everest Medicines’ Nefecon(R) far exceeded expectations. The institution significantly raised its revenue forecasts for 2026–2027 and lifted its target price to HK$84. The report highlighted a rich pipeline of catalysts from the second half of 2025 through 2026, including the approval, commercialization, and reimbursement negotiations of etrasimod in China, as well as potential BD opportunities for the Company’s proprietary pipeline. BOCOM International believes the current valuation remains attractive and reiterated its “Buy” rating.
“In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical company by deepening our ‘dual-engine’ strategy. We have built a commercialization platform anchored by two blockbusters covering high-potential markets and powered by the in-house discovery and clinical translation of in vivo CAR-T and mRNA therapeutic cancer vaccine platforms.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.
Core Products Deliver Strong Growth, Driving Commercial Platform Momentum
NEFECON(R), the blockbuster product in the renal portfolio, delivered particularly strong performance. As the first and only fully approved etiological treatment for IgA nephropathy (IgAN) in China, the United States, and Europe, NEFECON(R) generated revenue of RMB 303 million in the first half of 2025, representing 81% year-over-year growth. However, our first half revenue was artificially low due to a supply constraint that was rooted in both strong market demand and a delay in regulatory approval of a supplemental application for production scale up designed to ensure supply stability. This has been fully resolved since our supplemental application was approved by the China CDE on Aug 1, 2025. Following the supplemental application was approved by the China CDE in August, supply capacity increased significantly. Cumulative sales from January to August reached RMB 825 million, including RMB 520 million in August alone, reflecting strong market demand. Full-year sales are expected to reach RMB 1.2–1.4 billion, with continued strong growth projected in 2026, potentially reaching RMB 2.4–2.6 billion.
Another Core product XERAVA(R), As the world’s first fluorocycline antibiotic recorded RMB 143 million in the first half of 2025, up 6% year-over-year.
Click here to continue